Active Ingredients: Ciprofloxacin
The information is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate, or effective for you.
You should consult your health care professional before taking any drug, changing your diet, or commencing or discontinuing any course of treatment.
In a preferred embodiment, the reduced dose is maintained. Blood lymphocyte levels considered to be below clinically optimal levels can be assessed by a physician. For example, the lymphocyte level can be a level at which further reduction is judged to result in an increased risk of opportunistic infections without increasing clinical benefit.
For example, the lymphocyte level is 1. In certain embodiments, the blood lymphocyte level considered to be less than clinically optimal is a blood lymphocyte level of 0.
Blood lymphocyte levels can be measured using any standard technique, such as flow cytometry. In this embodiment, lymphocyte levels that are considered to be less than clinically optimal levels are 0.
In a preferred embodiment of this aspect, lymphocyte levels that are considered to be below clinically optimal levels can be 0. Patient genotype testing In vitro, CYP 2 C 9 was identified as the major metabolic enzyme in liver microsomes. Since this enzyme is genetically polymorphic, the effect of genetic polymorphism on oxidative metabolism was expected.
In order to handle this effect in vitro, in addition to traditional enzyme phenotyping approaches, an approach using individual microsomes from donors with genotype identified was designed. As will be appreciated by those skilled in the art, the patient's genotype plays an important role in determining the observed phenotype, ie, the observed ability of the CYP 2 C 9 enzyme to metabolize BAF 312.
Thus, genotypic testing is an excellent predictor of the observed phenotype.
To avoid misunderstandings, in certain embodiments of the invention, patient genotypes including whether the patient has a metabolized genotype or not can be tested by correlating with the observed phenotype.
Testing patient genotypes for patients belonging to the metabolic deficient subclass can be performed by any standard test method, eg, standard genotype determination methods such as PCR screening. Patient genotypes can be determined by in vitro test methods, such as genotype determination methods.
For example, in vitro testing involves collecting a body fluid eg, blood or saliva, such as blood or a tissue sample from a patient, and analyzing the sample by any standard test method eg, PCR screening.
Can be performed by determining patient genotypes.
In certain embodiments, the patient genotype is determined by analysis of blood, saliva or tissue samples taken from the patient. In a preferred embodiment, patient genotype is determined by analysis of a blood sample taken from the patient.
Substantial patient monitoring includes continuous or intermittent monitoring of the patient for adverse events by a physician or other skilled physician, such as in a medical institution such as a hospital or other treatment center.
The monitoring period can be 3 hours or more, for example, 6 hours or more, 12 hours or more, or 1 day or more. The monitoring period can be less than one week, eg, less than 4 days or less than 2 days.